Hostname: page-component-7c8c6479df-7qhmt Total loading time: 0 Render date: 2024-03-28T17:24:24.547Z Has data issue: false hasContentIssue false

Botulinum toxin as adjunctive therapy in refractory laryngeal granuloma

Published online by Cambridge University Press:  02 October 2007

E J Damrose*
Affiliation:
Department of Otolaryngology/Head and Neck Surgery, Stanford University Medical Center, CA, USA
J F Damrose
Affiliation:
Department of Otolaryngology, The Permanente Medical Group, Inc., Fresno, CA, USA
*
Address for correspondence: Dr Edward J Damrose, Department of Otolaryngology/Head and Neck Surgery, Stanford University Medical Center, 801 Welch Road, Stanford, CA 94305, USA. Fax: 650 725 8502 E-mail: edamrose@ohns.stanford.edu

Abstract

Objective:

This study evaluated the role of botulinum toxin type A in the treatment of refractory laryngeal granulomas.

Study design and setting:

Retrospective clinical review at a tertiary care hospital. Seven patients with vocal process granulomas underwent percutaneous injection of botulinum toxin into both vocal folds, performed in an office setting. Total doses ranged from 10 to 25 U, divided between both vocal folds.

Results:

All patients experienced resolution of their granulomas over two to seven weeks. No patient developed aspiration pneumonia. All patients experienced hoarseness secondary to the injections, but voice quality returned to baseline in all patients as the toxin was degraded.

Conclusions:

Botulinum toxin is safe and effective therapy in resolving vocal process granulomas in patients refractory to traditional therapy. The optimal treatment dose remains to be determined.

Significance:

Percutaneous botulinum toxin injection is helpful in resolving laryngeal granulomas.

Type
Main Article
Copyright
Copyright © JLO (1984) Limited 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Presented in part as a poster at the American Bronchoesophagological Association Annual Meeting, 14 May 2005, Boca Raton, Florida, USA.

References

1Havas, TE, Priestley, J, Lowinger, DS. A management strategy for vocal process granulomas. Laryngoscope 1999;109:301–6CrossRefGoogle ScholarPubMed
2de Lima Pontes, PA, De Biase, NG, Gadelha, MEC. Clinical evolution of laryngeal granulomas: treatment and prognosis. Laryngoscope 1999;109:289–94CrossRefGoogle ScholarPubMed
3Jackson, C, Jackson, CL. Contact ulcer of the larynx. Arch Otolaryngol 1935;22:115CrossRefGoogle Scholar
4Nasri, S, Sercarz, JA, McAlpin, T, Berke, GS. Treatment of vocal fold granuloma using botulinum toxin type A. Laryngoscope 1995;105:585–8CrossRefGoogle ScholarPubMed
5Orloff, LA, Goldman, SN. Vocal fold granulomas: successful treatment with botulinum toxin. Otolaryngol Head Neck Surg 1999;121:410–13CrossRefGoogle ScholarPubMed
6Green, DC, Berke, GS, Ward, PH, Gerratt, BR. Point-touch technique of botulinum toxin injection for the treatment of spasmodic dysphonia. Ann Otol Rhinol Laryngol 1992;11:883–7CrossRefGoogle Scholar
7Sulica, L, Blitzer, D. Operative Techniques in Otolaryngology/Head and Neck Surgery; Botulinum Toxin in the Treatment of Spasmodic Dysphonia. New York: Elsevier, 2004;76–9Google Scholar